Generic Times News
GENERIC BOOM FORECAST FOR 2011-2012
Published Online: Friday, June 1, 2007 [ ]
Brand name prescription drugs with annual sales of >$140 billion are in line to lose patent protection between now and 2016, according to a new analysis that bodes well for the generic pharmaceutical industry?s prospects during the coming decade. The analysis by researchers at Data-monitor predicts that the peak of the patent expirations will occur during 2011 and 2012, when heavily prescribed branded products such as clopi-dogrel bisulfate (Plavix), atorvas-tatin calcium (Lipitor), fluticasone propionate and salmeterol inhalation powder (Advair), and queti-apine fumarate (Seroquel) will face generic competition for the first time.
Your comments are valuable to us. Thank you.
Sorry, you must be logged in and registered to post a comment.
To login, click To register, click here.